索通發展(603612.SH):中瑞合作基金完成減持計劃 累計減持2%股份
格隆匯1月2日丨索通發展(603612.SH)公佈,截至2019年6月11日(減持計劃披露日),中瑞合作基金持有公司無限售流通股2059.93萬股,佔公司當時總股本的6.05%。
中瑞合作基金自2019年7月5日至2019年12月31日期間,通過集中競價方式減持合計673.97萬股,佔公司目前總股本的2.00%。截至本公告日,中瑞合作基金持有公司股份1385.96萬股,佔公司總股本的4.11%,本次減持計劃的減持時間區間屆滿。
公司於2019年6月25日完成325.22萬股限制性股票的回購註銷手續,公司總股本由3.40億股變更為3.37億股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.